Peripheral neuropathy decisions — 2025

The Board remands the claims for service connection for right and left lower extremity peripheral neuropathy due to a pre-decisional duty to assist error.

The Board granted increased ratings for the Veteran's right and left upper extremity diabetic neuropathy, as well as initial ratings for several lower extremity conditions, effective April 12, 2024.

The Board granted separate ratings of 20 percent for the Veteran's right and left lower extremity sciatic nerve neuritis and neuralgia, but denied higher initial ratings for diabetic neuropathy in both legs.

The Board remands the claims for service connection for diabetes mellitus type II and related conditions due to a lack of adequate medical evidence.

The Board granted special monthly compensation for loss of use of the feet and aid and attendance, but denied it for loss of use of the hands.

The Board remands the claims for service connection and special monthly compensation due to a pre-decisional duty to assist error, specifically related to toxic exposure risk activities under the PACT Act.

The Board granted an effective date of December 14, 2021, for the award of a 40 percent rating for left upper ulnar and median neuropathy.

The Board denied initial compensable ratings for right hip limitation of extension, flexion, and impairment, as well as an initial rating in excess of 10 percent for the right hip. The claim was also remanded to obtain a medical opinion on the Veteran's right upper extremity neuropathy and right lower extremity radiculopathy.

The appeal for an earlier effective date prior to August 29, 2014, for service connection for left and right lower extremity neuropathy was dismissed as there is no legal right to the benefit sought.

The appeals for effective dates and service connection were dismissed due to procedural defects and the Veteran's withdrawal of the appeal.

The Board remands the claims for a retrospective medical opinion regarding the severity of the Veteran's bilateral lower extremity neuropathy, as substantial compliance with prior remand directives was not achieved.

The Board dismissed the propriety of the referral of the matter of service connection for a left leg amputation and denied increased ratings for right and left lower extremity peripheral neuropathy.

The Board remands the matter of entitlement to TDIU for an additional Supplemental Statement of the Case due to new evidence and VA treatment records being associated with the file after the July 2024 SSOC.

The Board granted service connection for a depressive and anxiety disorder as secondary to the Veteran's service-connected conditions but denied increased ratings for peripheral neuropathy in all extremities.

The Board remands all claims for service connection due to a duty to assist error and the need to verify toxic exposure at Fort McClellan.

The Board denied service connection for rheumatoid arthritis, severe sinusitis, and peripheral neuropathy in the right upper extremity, right lower extremity, left upper extremity, and left lower extremity due to a lack of evidence linking these conditions to the Veteran's active duty service or exposure to contaminated water at Camp Lejeune.

The Board granted service connection for bilateral hallux rigidus and assigned a 60 percent rating from September 9, 2019, for residuals of prostate cancer with voiding dysfunction. It also granted ratings in excess of 20 percent for type II diabetes mellitus and right and left lower extremity peripheral neuropathy of the anterior crural nerve.

The Board remands the claims for compensation under 38 U.S.C. § 1151 for non-Hodgkin's lymphoma and related conditions to obtain records from the Veteran's FTCA claim.

The Board denied the Veteran's claims for an earlier effective date for service connection of left and right lower extremity diabetic peripheral neuropathy, as there were no pending claims prior to June 17, 2019.

The Board denied the claims for earlier effective dates, service connection for various conditions, and remanded some issues for further development.